Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hypertrophic cardiomyopathy in which the cause of the disease is a mutation in the PRKAG2 gene.
Features include always present findings: Shortened PR interval; and very common findings: Prolonged QRS complex. 16 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 9 | Aborted sudden cardiac death, Atrial fibrillation, Left bundle branch block |
PRKAG2 function has not been fully characterized.
Hypertrophic cardiomyopathy 6 is associated with mutations in the PRKAG2 gene on chromosome 7.
Hypertrophic cardiomyopathy 6 is included in newborn screening programs (3-Methylcrotonyl-CoA Carboxylase Deficiency) in 50 states.
Genetic testing for PRKAG2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hypertrophic cardiomyopathy 6 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature, 1 very common feature, 5 common features.
No clinical trials have been registered for hypertrophic cardiomyopathy 6.
242 publications have been identified in PubMed for hypertrophic cardiomyopathy 6. Research spans Clinical Trial Publication (27%), Epidemiology / Natural History (25%), and Review / Meta-Analysis (19%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 53 | 27% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 7:55 PM UTC
Online Mendelian Inheritance in Man
1 |
Wolff-Parkinson-White syndrome |
Disease patterns and progression
49 |
25% |
Research summaries | 38 | 19% |
Laboratory research | 23 | 12% |
Testing and diagnosis research | 21 | 11% |
Patient case studies | 9 | 5% |
Other research | 4 | 2% |
New treatment approaches | 2 | 1% |
Bjerregaard L (2026). [PMID: 41778690](https://pubmed.ncbi.nlm.nih.gov/41778690/). *J Am Coll Cardiol*. [Clinical Trial Publication]
Dinesen RB (2026). [PMID: 42054027](https://pubmed.ncbi.nlm.nih.gov/42054027/). *JAMA Netw Open*. [Clinical Trial Publication]
Wang X (2026). [PMID: 41205225](https://pubmed.ncbi.nlm.nih.gov/41205225/). *Circ Heart Fail*. [Clinical Trial Publication]
Usai P (2026). [PMID: 41711735](https://pubmed.ncbi.nlm.nih.gov/41711735/). *ESC Heart Fail*. [Clinical Trial Publication]
Shirley M (2026). [PMID: 41941083](https://pubmed.ncbi.nlm.nih.gov/41941083/). *Drugs*. [Review / Meta-Analysis]
Lee MMY (2026). [PMID: 41093262](https://pubmed.ncbi.nlm.nih.gov/41093262/). *Prog Cardiovasc Dis*. [Review / Meta-Analysis]
Österberg AW (2026). [PMID: 40472950](https://pubmed.ncbi.nlm.nih.gov/40472950/). *Heart Rhythm*. [Epidemiology / Natural History]
Suwa K (2026). [PMID: 41129543](https://pubmed.ncbi.nlm.nih.gov/41129543/). *J Magn Reson Imaging*. [Clinical Trial Publication]
Zhu C (2026). [PMID: 40368289](https://pubmed.ncbi.nlm.nih.gov/40368289/). *Heart Rhythm*. [Epidemiology / Natural History]
Tian Z (2026). [PMID: 42179278](https://pubmed.ncbi.nlm.nih.gov/42179278/). *J Am Heart Assoc*. [Clinical Trial Publication]